Clinical Trials
17 trialsNCT06507748 2026-06-05
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT00924196 2026-06-04
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT06222203 2026-06-04
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03975829 2026-06-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT01362803 2026-06-01
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT02390752 2026-06-01
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02544022 2026-06-01
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06360406 2026-06-01
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Recruiting
NCT06188741 2026-05-29
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07407803 2026-05-27
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT06541847 2026-05-19
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT04590235 2026-05-14
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT06175637 2026-05-13
PEDIA
AstraZeneca
Active not recruiting
NCT05028166 2026-05-08
Individual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT03962543 2026-05-06
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT03363217 2026-04-24
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Phase 2 Active not recruiting
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting